Cargando…
Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
The prognosis of malignant gliomas remains poor, with median survival fewer than 20 months and a 5-year survival rate merely 5%. Their primary location in the central nervous system (CNS) and its immunosuppressive environment with little T cell infiltration has rendered cancer therapies mostly ineff...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8524046/ https://www.ncbi.nlm.nih.gov/pubmed/34675919 http://dx.doi.org/10.3389/fimmu.2021.721830 |